Well, when you sell you don't usually hang around. I usually make a profit and leave. Sometimes it takes a while and sometimes it doesn't. Sometimes you cut your losses, but only a fool would pay $135 for a stock and ride it down to nothing. So you are either a liar or a fool in either case I would not pay much attention to you.
Looks like a supplier is gearing up for big demand. Demand driven by an expected good trial results?Looks like they don't expect it to take two more years either.
" Japan's Nissui bets big on fatty acids"
TOKYO A fatty acid found in the flesh of cold-water fish is believed to boost both brain function and cardiovascular health in humans. It may also be a key to the future fiscal health of Japan's Nippon Suisan Kaisha.
Nissui, as the company is known, is spending 8 billion yen ($72.4 million) on a new plant to produce eicosapentaenoic acid, or EPA, as it steps up investment outside its century-old mainstay seafood business. The company's share price has risen amid an aggressive restructuring effort that also includes cost-cutting and expanding in overseas markets including the U.S. and China.
The seafood company, Japan's second largest, reported record-high group net profit for the second straight year in the 12 months ended March. Its fisheries business posted 269.6 billion yen in sales, or 42% of the total. However, operating profit for the business fell 35.8% due to unfavorable market conditions.
The company's worst performer last year was its salmon and trout aquaculture business in Chile. Demand in Russia, a major consumer of the two fish, has dropped as the country's economy weakens amid international sanctions and declining oil prices. As a result, salmon and trout prices have fallen, forcing Nissui to log a valuation loss on the fish farm.
BETTING ON EPA "
So I would guess that would mean that other participants are down also. The first quarter is known to be a downer....Dah. But you always have an option to listen to Joe if you are inclined to pay attention to stupidity.
"$AMRN pump and dump. No volume. Authomatic trade. Pathetic pumpers. Terrible cash burn. Pathetic scripts. All ok in amrn s world"
Another demoralized, cry baby Short. Hahaha.
Amarin Corp. (NASDAQ: AMRN) was assumed with a Buy rating and a $3.50 price target (versus a $1.57 prior close) at Jefferies on May 12. The firm said it believes that the off-label Vascepa promotion in mixed dyslipidemia may be starting to bear fruit. It said:
We believe off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit, where our analysis of TRx data suggests a steeper upward trend in recent months v. 2015. Access to this population is a major source of upside, where we see opportunity of $2.5 billion. Focus is also on REDUCE-IT where we believe Vascepa can show a benefit on final analysis in early 2018, and upside could be $14 per share.
Amarin closed on Friday at $1.72. It has a consensus target price of $6.50 and a 52-week trading range "
Our system’s recommendation today is to STAY LONG. The previousBUY signal was issued on 05/16/2016, 4 days ago, when the stock price was 1.65. Since then AMRN has risen by +4.56%."
"Decision on naked short case seen opening door for state suits
Ruling could apply to other securities-law cases, lawyer says
The U.S. Supreme Court dealt a blow to financial services firms trying to fend off allegations that they facilitate illegal short selling, affirming the rights of investors to make their case in plaintiff-friendly state courts.
With the court’s ruling on Monday, plaintiffs may find that such suits have a greater chance of advancing in a state court, potentially exposing brokerages to more expensive litigation, said Sam Lieberman, a partner at Sadis & Goldberg LLP.
“It’s easier to have your case thrown out for procedural reasons in federal court,” Lieberman said. “In state courts, you’re more likely to get closer to trial, and get closer to trial means you’re more likely to get closer to settling.”
New Jersey and other states also have Racketeer Influenced and Corrupt Organizations Act statutes aimed at organized crime that could be applied broadly enough to cover the conduct of financial services firms, said David Zaring, a professor of legal studies and business at University of Pennsylvania’s Wharton School of Business.
“New Jersey’s RICO statute might look like an easier route to a jury,” he said.
Siding With Investors
In a unanimous ruling Monday, the Supreme Court sided with investors who sued Bank of America Corp.’s Merrill Lynch and other brokerage firms. At issue was whether the plaintiffs, who alleged they lost money because of the brokers’ involvement in illegal short selling, could use New Jersey state court to sue over their losses -- even if the litigation cited federal laws.
The ruling forces Merrill Lynch, Bank of America’s corporate and investment banking division, and other firms to mount a defense in New Jersey state court. The plaintiffs in the case are using the state’s RICO statute as part of their complaint.
While concerned with so-called naked short selling, the ruling could potentiall